Netherlands-based holding company QIAGEN N.V. (NYSE: QGEN) (Frankfurt Prime Standard: QIA) announced on Monday that it unveiled QIAsymphony Connect, the next generation of its automated nucleic acid purification platform, at the Association for Molecular Pathology (AMP) 2025 annual meeting in Boston. The new system enters early access ahead of full commercial release in mid-2026.

Building on more than 3,000 cumulative placements of the first-generation platform, QIAsymphony Connect delivers faster throughput, improved nucleic acid recovery and full sample traceability through automated barcode tracking. The platform also offers enhanced connectivity with laboratory information systems and QIAsphere, QIAGEN's cloud-based workflow platform. Optimised for liquid biopsy and minimal residual disease monitoring, the system boosts capacity by up to 50% in select protocols while reducing processing time and sample loss.

At AMP 2025, QIAGEN is also showcasing advances in precision oncology through its Sample to Insight workflows, highlighting collaborations with Element Biosciences and Myriad Genetics Inc (NASDAQ: MYGN).

A joint workshop with Element Biosciences on 12 November will present early-access data on a comprehensive genomic profiling workflow for breast cancer FFPE samples using QIAseq xHYB Trinity CGP on the Trinity platform. Commercial launch is expected in early 2026.

In partnership with Myriad Genetics, QIAGEN is advancing development of a homologous recombination deficiency (HRD) assay. Early results from the QIAseq xHYB HRD Panel, used in a Sample to Insight workflow, show high concordance with Myriad's MyChoice® CDx assay, with full commercialisation (excluding Japan) planned for early 2026.

QIAGEN serves over 500,000 customers globally across life sciences and molecular diagnostics, employing approximately 5,700 people in more than 35 locations as of 30 September 2025.